Study of AMG 160 in Subjects with Non-Small Cell Lung Cancer

- Participant has provided informed consent prior to initiation of any study specific activities/procedures. - Histologically or cytologically confirmed stage 4 or recurrent non-squamous NSCLC (Part 1); histologically or cytologically. confirmed stage 4 or recurrent NSCLC (Part 2 only, squamous cell histology/cytology allowed in Part 2). - Without a driver mutation: disease progression following at least one line of prior chemotherapy and at least 1 prior anti-programmed cell death protein 1 (PD1)/programmed death-ligand 1 (PDL1) therapy. - With a driver mutation must experience disease progression on at least 1 targeted therapeutic agent to be eligible. - Detectable prostate-specific membrane antigen (PSMA) expression by PSMA positron emission tomography (PET)/computed tomography (CT) imaging. - Measurable disease by modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. - Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0- 2.

- Radiographic evidence of intratumor cavitation, major blood vessel invasion or encasement by cancer. - Untreated or symptomatic brain metastases and leptomeningeal disease. - History of hemoptysis within 3 months prior to first dose. - History or evidence of gastrointestinal inflammatory bowel disease (ulcerative colitis or Crohn disease). - Myocardial infarction, unstable angina, cardiac arrhythmias requiring medication, and/or symptomatic congestive heart failure (New York Heart Association > class II) within 12 months prior to start of dosing. - Vasculitis or grade 3/4 gastrointestinal bleeding within 3 months prior to first dose; vascular disease (eg, aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months of first dose. - Gastrointestinal (GI) perforation and/or fistulae within 6 months prior to start of dosing. - Interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with treatment. - Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation). - Chronic systemic corticosteroid therapy or any other immunosuppressive therapies unless stopped 7 days prior to first dose. - Any biological therapy or immunotherapy within 3 weeks of start of first dose. - Major surgery within 4 weeks of first dose. - Infection requiring IV antimicrobials for management within 7 days of dosing. - Known human immunodeficiency virus (HIV) infection, hepatitis C infection. - Active autoimmune disease